Samanta Salvi

Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study.

Copy number analysis of 24 oncogenes: MDM4 identified as a putative marker for low recurrence risk in non muscle invasive bladder cancer.

Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients.

Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Plasma AR and abiraterone-resistant prostate cancer.

CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone.

Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy.

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.

miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer.

Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach.

GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications.

The potential use of urine cell free DNA as a marker for cancer.

Cell-free DNA as a diagnostic marker for cancer: current insights.

Digital PCR identifies changes in CDH1 (E-cadherin) transcription pattern in intestinal-type gastric cancer.

Vitamin D status among long-term survivors of testicular cancer.

Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer.

Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.